FDA approves Hibsago, the first antisense drug for chronic hepatitis B
The FDA approves Hibsago, the first antisense drug for chronic hepatitis B, the Philips Lumify ultrasound correction becomes a Class I recall after four deaths, and a Maryland lab owner is convicted of Medicare fraud.
HealthSplash owner sentenced to 19 years for $1 billion Medicare brace fraud
The HealthSplash owner gets 19 years for a $1 billion Medicare brace fraud, the FDA flags an Edwards mitral valve delivery system after a death, and Anktiva’s bladder cancer indication expands.